NYSE:ARA - American Renal Associates Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.51 -2.19 (-13.95 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$15.70
Today's Range$13.2950 - $15.3824
52-Week Range$13.30 - $24.07
Volume256,524 shs
Average Volume161,406 shs
Market Capitalization$521.90 million
P/E Ratio22.15
Dividend YieldN/A
Beta2.01
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:ARA
Previous Symbol
CUSIPN/A
Phone978-922-3080

Debt

Debt-to-Equity Ratio5.48
Current Ratio1.03
Quick Ratio1.00

Price-To-Earnings

Trailing P/E Ratio22.15
Forward P/E Ratio23.29
P/E Growth4.37

Sales & Book Value

Annual Sales$745.11 million
Price / Sales0.59
Cash Flow$1.6103 per share
Price / Cash Flow8.39
Book Value$3.83 per share
Price / Book3.53

Profitability

EPS (Most Recent Fiscal Year)$0.61
Net Income$4.85 million
Net Margins-1.81%
Return on Equity22.30%
Return on Assets2.41%

Miscellaneous

Employees4,692
Outstanding Shares32,520,000
Market Cap$521.90 million
OptionableOptionable

American Renal Associates (NYSE:ARA) Frequently Asked Questions

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) posted its quarterly earnings data on Thursday, November, 8th. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.06. The company earned $211.02 million during the quarter, compared to analyst estimates of $217.15 million. American Renal Associates had a negative net margin of 1.81% and a positive return on equity of 22.30%. The business's quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.19 earnings per share. View American Renal Associates' Earnings History.

When is American Renal Associates' next earnings date?

American Renal Associates is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for American Renal Associates.

What price target have analysts set for ARA?

5 equities research analysts have issued 1-year price objectives for American Renal Associates' stock. Their forecasts range from $16.00 to $26.00. On average, they expect American Renal Associates' stock price to reach $21.80 in the next year. This suggests a possible upside of 61.4% from the stock's current price. View Analyst Price Targets for American Renal Associates.

What is the consensus analysts' recommendation for American Renal Associates?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for American Renal Associates.

Has American Renal Associates been receiving favorable news coverage?

Media headlines about ARA stock have trended somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. American Renal Associates earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of American Renal Associates' key competitors?

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the folowing people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 64)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 65)
  • Mr. Jason M. Boucher, VP & CFO (Age 46)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 55)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.

When did American Renal Associates IPO?

(ARA) raised $161 million in an initial public offering on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Van Berkom & Associates Inc. (7.71%), Franklin Resources Inc. (3.80%), Vanguard Group Inc (3.56%), Vanguard Group Inc. (3.56%), BlackRock Inc. (2.94%) and JPMorgan Chase & Co. (2.13%). View Institutional Ownership Trends for American Renal Associates.

Which institutional investors are selling American Renal Associates stock?

ARA stock was sold by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Citadel Advisors LLC, Acadian Asset Management LLC, Van Berkom & Associates Inc., Alambic Investment Management L.P., Man Group plc, Strs Ohio and Taylor Cottrill Erickson & Associates Inc.. View Insider Buying and Selling for American Renal Associates.

Which institutional investors are buying American Renal Associates stock?

ARA stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., Franklin Resources Inc., Renaissance Technologies LLC, Cadence Capital Management LLC, Vanguard Group Inc, Vanguard Group Inc. and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for American Renal Associates.

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $13.51.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $521.90 million and generates $745.11 million in revenue each year. The company earns $4.85 million in net income (profit) each year or $0.61 on an earnings per share basis. American Renal Associates employs 4,692 workers across the globe.

What is American Renal Associates' official website?

The official website for American Renal Associates is http://www.americanrenal.com.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]


MarketBeat Community Rating for American Renal Associates (NYSE ARA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about American Renal Associates and other stocks. Vote "Outperform" if you believe ARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel